Journal of Emergency Health Care
Formerly known as: International Journal of Medical Investigation
Volume 13, Issue 2 (6-2024)
J Emerg Health Care 2024, 13(2): 24-31 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shakeri M, Parpaei M, Pour H A R, Rahmanian Z. The Impact of Proton Pump Inhibitors (PPIs) on the Gut Microbiome: A Narration of literature. J Emerg Health Care 2024; 13 (2) :24-31
URL: http://intjmi.com/article-1-1158-en.html
URL: http://intjmi.com/article-1-1158-en.html
Department of Internal Medicine, Jahrom University of Medical Sciences, Jahrom, Iran.
Abstract: (601 Views)
Background: Proton pump inhibitors (PPIs) are widely used to treat acid-related disorders, but their impact on the gut microbiome is not well understood. To review the evidence on the effects of PPIs on the gut microbiome and their potential consequences for human health.
Methods: A narrative review of published studies on the impact of PPIs on the gut microbiome was conducted.
Results: PPIs have been shown to alter the balance of gut bacteria, leading to an increased risk of various diseases, including Clostridioides difficile infections, insulin resistance, and elevated blood sugar levels. PPIs have also been found to have a negative impact on specific populations, such as infants and young children. In contrast, some studies have suggested that PPIs may not directly affect the balance of gut bacteria, but rather alter the gut pH, leading to changes in the microbiome.
Conclusion: The evidence suggests that PPIs can have a significant impact on the gut microbiome, leading to negative consequences for human health. Further research is needed to fully understand the effects of PPIs on the gut microbiome and to identify potential strategies for mitigating these effects.
Methods: A narrative review of published studies on the impact of PPIs on the gut microbiome was conducted.
Results: PPIs have been shown to alter the balance of gut bacteria, leading to an increased risk of various diseases, including Clostridioides difficile infections, insulin resistance, and elevated blood sugar levels. PPIs have also been found to have a negative impact on specific populations, such as infants and young children. In contrast, some studies have suggested that PPIs may not directly affect the balance of gut bacteria, but rather alter the gut pH, leading to changes in the microbiome.
Conclusion: The evidence suggests that PPIs can have a significant impact on the gut microbiome, leading to negative consequences for human health. Further research is needed to fully understand the effects of PPIs on the gut microbiome and to identify potential strategies for mitigating these effects.
Keywords: Proton pump inhibitors, Gut microbiome, Clostridioides difficile infections, Insulin resistance, Acid-related disorders, Gastrointestinal health
References
1. 1. Ogunrinola GA, Oyewale JO, Oshamika OO, Olasehinde GI. The human microbiome and its impacts on health. International journal of microbiology. 2020;2020(1):8045646.
2. Pflughoeft KJ, Versalovic J. Human microbiome in health and disease. Annual Review of Pathology: Mechanisms of Disease. 2012 Feb 28;7(1):99-122.
3. Johnson JS, Spakowicz DJ, Hong BY, Petersen LM, Demkowicz P, Chen L, Leopold SR, Hanson BM, Agresta HO, Gerstein M, Sodergren E. Evaluation of 16S rRNA gene sequencing for species and strain-level microbiome analysis. Nature communications. 2019 Nov 6;10(1):5029
4. Park SY, Hwang BO, Lim M, Ok SH, Lee SK, Chun KS, Park KK, Hu Y, Chung WY, Song NY. Oral–gut microbiome axis in gastrointestinal disease and cancer. Cancers. 2021 Apr 28;13(9):2124.
5. Kunath BJ, De Rudder C, Laczny CC, Letellier E, Wilmes P. The oral–gut microbiome axis in health and disease. Nature Reviews Microbiology. 2024 Jul 22:1-5.
6. du Teil Espina M, Gabarrini G, Harmsen HJ, Westra J, van Winkelhoff AJ, van Dijl JM. Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis. FEMS microbiology reviews. 2019 Jan;43(1):1-8.
7. Wang A, Zhai Z, Ding Y, Wei J, Wei Z, Cao H. The oral-gut microbiome axis in inflammatory bowel disease: from inside to insight. Frontiers in Immunology. 2024 Jul 26;15:1430001.
8. Amato A. Oral-Systemic Health and Disorders: Latest Advances on Oral–Gut–Lung Microbiome Axis. Applied Sciences. 2022 Aug 17;12(16):8213.
9. Liu F, Su D, Zhang H, Lin HC, Zhou Q, Cao B, Ren DL. Clinical implications of the oral gut microbiome axis and its association with colorectal cancer. Oncology Reports. 2022 Nov 1;48(5):1-8.
10. Narengaowa, Kong W, Lan F, Awan UF, Qing H, Ni J. The oral-gut-brain AXIS: the influence of microbes in Alzheimer’s disease. Frontiers in cellular neuroscience. 2021 Apr 14;15:633735.
11. Minalyan A, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The gastric and intestinal microbiome: role of proton pump inhibitors. Current gastroenterology reports. 2017 Aug;19:1-0.
12. Imhann F, Bonder MJ, Vila AV, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G. Proton pump inhibitors affect the gut microbiome. Gut. 2016 May 1;65(5):740-8.
13. Putignani L, Del Chierico F, Petrucca A, Vernocchi P, Dallapiccola B. The human gut microbiota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatric research. 2014 Jul;76(1):2-10.
14. Mesa MD, Loureiro B, Iglesia I, Fernandez Gonzalez S, Llurba Olivé E, Garcia Algar O, Solana MJ, Cabero Perez MJ, Sainz T, Martinez L, Escuder-Vieco D. The evolving microbiome from pregnancy to early infancy: a comprehensive review. Nutrients. 2020 Jan 2;12(1):133.
15. Leeming ER, Johnson AJ, Spector TD, Le Roy CI. Effect of diet on the gut microbiota: rethinking intervention duration. Nutrients. 2019 Nov 22;11(12):2862.
16. Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, Nikkïla J, Monti D, Satokari R, Franceschi C, Brigidi P. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PloS one. 2010 May 17;5(5):e10667.
17. Ghaemi F, Fateh A, Sepahy AA, Zangeneh M, Ghanei M, Siadat SD. Intestinal microbiota composition in Iranian diabetic, pre-diabetic and healthy individuals. Journal of Diabetes & Metabolic Disorders. 2020 Dec;19:1199-203.
18. Papaioannou W, Gizani S, Haffajee AD, Quirynen M, Mamai‐Homata E, Papagiannoulis L. The microbiota on different oral surfaces in healthy children. Oral microbiology and immunology. 2009 Jun;24(3):183-9.
19. Zhang Y, Wang X, Li H, Ni C, Du Z, Yan F. Human oral microbiota and its modulation for oral health. Biomedicine & Pharmacotherapy. 2018 Mar 1;99:883-93.
20. Nearing JT, DeClercq V, Van Limbergen J, Langille MG. Assessing the variation within the oral microbiome of healthy adults. Msphere. 2020 Oct 28;5(5):10-128.
21. Sachs G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibitors. Alimentary pharmacology & therapeutics. 2006 Jun;23:2-8.
22. Pottegård A, Broe A, Hallas J, de Muckadell OB, Lassen AT, Lødrup AB. Use of proton-pump inhibitors among adults: a Danish nationwide drug utilization study. Therapeutic advances in gastroenterology. 2016 Sep;9(5):671-8.
23. Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. European journal of clinical pharmacology. 2020 Mar;76:449-57.
24. Vesper BJ, Jawdi A, Altman KW, Haines Iii GK, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Current drug metabolism. 2009 Jan 1;10(1):84-9.
25. van Vlerken LG, Huisman EJ, van Hoek B, Renooij W, de Rooij FW, Siersema PD, van Erpecum KJ. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability. European Journal of Clinical Investigation. 2012 Jul;42(7):760-7.
26. Saniee P, Shahreza S, Siavoshi F. Negative effect of proton‐pump inhibitors (PPI s) on Helicobacter pylori growth, morphology, and urease test and recovery after PPI removal–an in vitro study. Helicobacter. 2016 Apr;21(2):143-52.
27. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary pharmacology & therapeutics. 2011 Dec;34(11‐12):1269-81.
28. Campbell MS, Obstein K, Reddy KR, Yang YX. Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Digestive diseases and sciences. 2008 Feb;53:394-8.
29. Xiao X, Zhang X, Wang J, Liu Y, Yan H, Xing X, Yang J. Proton pump inhibitors alter gut microbiota by promoting oral microbiota translocation: a prospective interventional study. Gut. 2024 Jul 1;73(7):1098-109.
30. Zhu J, Sun C, Li M, Hu G, Zhao XM, Chen WH. Compared to histamine-2 receptor antagonist, proton pump inhibitor induces stronger oral-to-gut microbial transmission and gut microbiome alterations: a randomised controlled trial. Gut. 2024 Jul 1;73(7):1087-97.
31. Lee I, Jo JW, Woo HJ, Suk KT, Lee SS, Kim BS. Proton pump inhibitors increase the risk of carbapenem-resistant Enterobacteriaceae colonization by facilitating the transfer of antibiotic resistance genes among bacteria in the gut microbiome. Gut Microbes. 2024 Dec 31;16(1):2341635.
32. He Q, Xia B, Yang M, Lu K, Fan D, Li W, Liu Y, Pan Y, Yuan J. Alterations in gut microbiota and bile acids by proton‐pump inhibitor use and possible mediating effects on elevated glucose levels and insulin resistance. The FASEB Journal. 2024 Mar 31;38(6):e23541.
33. Schumacher J, Mueller P, Sulzer J, Faber F, Molitor B, Maier L. Proton-pump inhibitors increase C. difficile infection risk by altering pH rather than by affecting the gut microbiome based on a bioreactor model. bioRxiv. 2024:2024-07.
34. Kim JW, Jeong Y, Park SJ, Jin H, Lee J, Ju JH, Ji GE, Park SH. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. Rheumatology. 2021 Feb 1;60(2):708-16.
35. Brusselaers N, Pereira M, Alm J, Engstrand L, Engstrand Lilja H. Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort. Gut pathogens. 2022 Dec 16;14(1):47.
36. Levy EI, Hoang DM, Vandenplas Y. The effects of proton pump inhibitors on the microbiome in young children. Acta Paediatrica. 2020 Aug;109(8):1531-8.
37. Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, Hayashi A, Jodai T, Akaike K, Anai M, Hamada S. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. Oncoimmunology. 2022 Dec 31;11(1):2081010.
38. Lim JH, Shin J, Park JS. Effect of a proton pump inhibitor on the duodenum microbiome of gastric ulcer patients. Life. 2022 Sep 27;12(10):1505.
39. Lin CY, Cheng HT, Kuo CJ, Lee YS, Sung CM, Keidan M, Rao K, Kao JY, Hsieh SY. Proton pump inhibitor-induced gut dysbiosis increases mortality rates for patients with clostridioides difficile infection. Microbiology Spectrum. 2022 Aug 31;10(4):e00486-22.
40. Tanigawa T, Watanabe T, Higashimori A, Shimada S, Kitamura H, Kuzumoto T, Nadatani Y, Otani K, Fukunaga S, Hosomi S, Tanaka F. Rebamipide ameliorates indomethacin-induced small intestinal damage and proton pump inhibitor-induced exacerbation of this damage by modulation of small intestinal microbiota. PLoS One. 2021 Jan 28;16(1):e0245995.
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |